Protected Class Lobbying Begins: Bayer Seeks Protection For MS Therapy
Executive Summary
Bayer Healthcare is asking CMS to expand Medicare Part D protected class status to immunomodulators used to treat multiple sclerosis
You may also be interested in...
Part D Protected Classes: Manufacturers, Payers Agree On Need For Specifics
Both levels of review for determining protected classes under Medicare Part D could stand to have more specific guidelines on the selection of participants and on what drug information is to be considered, manufacturers and payers told CMS in comments
Genzyme Strengthens Oncology And MS Portfolios With Bayer Deal
The complicated deal bolsters Genzyme’s developing oncology franchise and provides a potential MS blockbuster without requiring an up-front payment.
CMS Opens Way To Add, Or Subtract, Protected Classes In Part D Formularies
CMS is creating a multi-step process that will give outside experts and the public a role in adding or subtracting "protected" drug classes in Medicare Part D, as well as making exceptions to the rule that all drugs must be covered in a protected class